Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Biofrontera Inc. Warrants (BFRIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: BFRIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.08% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.3 | 52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 |
52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.33% | Operating Margin (TTM) -52.95% |
Management Effectiveness
Return on Assets (TTM) -49.47% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 7102407 |
Shares Outstanding - | Shares Floating 7102407 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biofrontera Inc. Warrants
Company Overview
History and Background
Biofrontera Inc. is a biopharmaceutical company focused on the development and commercialization of medical products for dermatological and aesthetic applications. The company was founded in 1997 in Germany. Biofrontera's US listing, Biofrontera Inc. Warrants, represents options to purchase shares of the parent company. Significant milestones include the FDA approval of its flagship product, Xepiu00ae (minocycline topical foam), for the treatment of impetigo. The company has undergone several financing rounds and strategic partnerships to fund its growth and product development.
Core Business Areas
- Dermatology Therapeutics: Development and commercialization of prescription drugs for dermatological conditions, primarily focusing on skin cancer and inflammatory skin diseases.
- Aesthetic Products: Offering of medical devices and cosmetic products for aesthetic treatments.
Leadership and Structure
Biofrontera AG, the parent company, is led by a management board and overseen by a supervisory board. Key executives include the CEO, CFO, and CSO. Biofrontera Inc. is the US subsidiary, likely with its own leadership team responsible for US operations, but ultimately reporting to the parent company.
Top Products and Market Share
Key Offerings
- Description: FDA-approved topical antibiotic foam for the treatment of impetigo in adult and pediatric patients. Market share data is not readily available, but it competes in the topical antibiotic market. Competitors include topical antibiotics like mupirocin (e.g., Bactroban) and retapamulin (e.g., Altabax).
- Product Name 1: Xepiu00ae (minocycline topical foam)
- Description: FDA-approved topical photodynamic therapy (PDT) agent for the treatment of actinic keratosis (AK) on the face and scalp. Market share data is not publicly disclosed. Competitors in the PDT market include other ALA-based products and devices.
- Product Name 2: Ameluzu00ae (aminolevulinic acid hydrochloride) gel
Market Dynamics
Industry Overview
The dermatology market, particularly for prescription therapeutics and aesthetic treatments, is a significant and growing sector driven by an aging population, increased awareness of skin health, and advancements in treatment technologies. The biopharmaceutical sector faces stringent regulatory hurdles and high R&D costs.
Positioning
Biofrontera Inc. is a niche player in the dermatology space, focusing on specific indications like impetigo and actinic keratosis. Its competitive advantage lies in its FDA-approved products and its growing commercial infrastructure in the US. However, it faces competition from larger, more established pharmaceutical companies and emerging biotech firms.
Total Addressable Market (TAM)
The TAM for impetigo treatment and actinic keratosis treatment is substantial, with millions of cases diagnosed annually globally. Biofrontera Inc. is positioned to capture a segment of this market with its specialized therapies. Precise TAM figures vary depending on the specific indication and geographic scope.
Upturn SWOT Analysis
Strengths
- FDA-approved products with clear indications.
- Proprietary technology for drug delivery.
- Established commercial presence in the US market.
- Focus on niche but significant dermatological areas.
Weaknesses
- Limited product portfolio compared to larger pharmaceutical companies.
- Dependence on a few key products for revenue.
- Potential for significant cash burn due to R&D and commercialization efforts.
- Competition from established players with larger marketing budgets.
Opportunities
- Expansion of product indications into other dermatological conditions.
- Partnerships and licensing agreements to broaden reach.
- Geographic expansion beyond the US market.
- Advancements in dermatological research leading to new product development.
Threats
- Intense competition from established pharmaceutical companies.
- Changes in regulatory landscape and reimbursement policies.
- Patent expirations and the emergence of generic alternatives.
- Challenges in clinical trial success for new drug candidates.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Sun Pharmaceutical Industries Ltd. (India) (US Stock Symbol: SUNP)
- Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.) (US Stock Symbol: BHC)
- Novartis AG (US Stock Symbol: NVS)
- AbbVie Inc. (US Stock Symbol: ABBV)
Competitive Landscape
Biofrontera Inc. operates in a highly competitive landscape dominated by larger pharmaceutical companies with extensive R&D pipelines and marketing resources. Its advantages lie in its specialized focus and approved niche products, while its disadvantages stem from its smaller size, limited pipeline breadth, and reliance on a few key products.
Growth Trajectory and Initiatives
Historical Growth: Biofrontera Inc. has demonstrated historical growth through successful product approvals and commercial launches in its key markets. Revenue has seen an upward trend as its product portfolio matures.
Future Projections: Future growth projections are typically based on analyst estimates and depend on the successful execution of the company's commercial strategy, potential new product approvals, and market adoption rates. Analysts may project continued revenue growth with a focus on achieving profitability.
Recent Initiatives: Expansion of the sales force to increase market penetration for Xepiu00ae and Ameluzu00ae.,Ongoing clinical studies for potential new indications or product improvements.,Strategic collaborations and partnerships to enhance market access or distribution.
Summary
Biofrontera Inc. Warrants offer exposure to a biopharmaceutical company with a focused portfolio of dermatology products. The company has demonstrated success in gaining FDA approvals and establishing a US commercial presence. However, it operates in a competitive market and faces challenges related to R&D investment and achieving consistent profitability. Continued growth hinges on expanding its product pipeline and effectively competing against larger, established players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q for Biofrontera AG and Biofrontera Inc.)
- Financial news outlets and market data providers
- Industry reports on the dermatology market
Disclaimers:
This JSON output is generated for informational purposes only and should not be considered as financial advice. Stock market investments are subject to risks. Users should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data and competitor information are estimates and may not be fully comprehensive or up-to-date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc. Warrants
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.